A multicenter, prospective, randomized, comparative evaluation of dual- versus triple-lumen catheters for hemodialysis and apheresis in 485 patients

Gabriel Contreras, Ping Yu Liu, Lawrence Elzinga, Michael S. Anger, Jean Lee, Nurian Robert, Robert Chvala, Ronald L. Mars, Thomas Vesely, Tim Taber, Douglas Shemin, Randy Shafritz, Joseph Pulliam

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: The purpose of this study is to compare a new temporary triple-lumen catheter (TLC) for dialysis that has a third lumen devoted to fluid and medication administration or blood sampling with a marketed dual-lumen catheter (DLC). Methods: Four hundred eighty-five patients referred for acute hemodialysis or apheresis were randomly assigned to either a TLC or DLC in a multicenter, prospective, randomized trial. Results: Analysis of blood flow rates was completed on 464 patients (228 patients, DLC; 236 patients, TLC) with a total of 1,681 hemodialysis (808 treatments, DLC; 873 treatments, TLC) and 82 apheresis treatments (37 treatments, DLC; 45 treatments, TLC). During hemodialysis, a median achieved flow rate (AFR) of 267 mL/min was realized for both groups (P = 0.58). During apheresis, a median AFR of 72.5 mL/min (range, 50 to 150 mL/min) was achieved in the DLC group, and 87 mL/min (range, 60 to 150 mL/min), in the TLC group (P = 0.14). Three hundred ninety-three patients (193 patients, DLC; 200 patients, TLC) had blood and catheter tip cultures performed on removal, and catheter-related blood-stream infection (CRBSI) status was determined. Thirty-one patients (7.9%) had a CRBSI: 16 patients (8.3%), DLC; and 15 patients (7.5%), TLC (P= 0.77). Incidence densities of CRBSI were 12.4/1,000 DLC-days and 10.2/1,000 TLC-days (P = 0.59). The CRBSI incidence of 18.2/1,000 catheter-days for femoral sites was significantly greater than the 7/1,000 catheter-days for jugular sites (P = 0.02) and 6.6/1,000 catheter-days for combined jugular and subclavian sites (P = 0.01). In multivariate analysis, antibiotic use was the only factor related to CRBSI (odds ratio, 0.30; 95% confidence interval, 0.12 to 0.76). There were no statistically significant differences in rates of other complications between the 2 catheters. Conclusion: Results show that the new TLC is similar to the marketed DLC.

Original languageEnglish (US)
Pages (from-to)315-324
Number of pages10
JournalAmerican Journal of Kidney Diseases
Volume42
Issue number2
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Blood Component Removal
Renal Dialysis
Catheters
Infection

Keywords

  • Apheresis
  • Hemodialysis (HD)
  • Randomized clinical trial
  • Temporary triple-lumen catheter (TLC)

ASJC Scopus subject areas

  • Nephrology

Cite this

A multicenter, prospective, randomized, comparative evaluation of dual- versus triple-lumen catheters for hemodialysis and apheresis in 485 patients. / Contreras, Gabriel; Liu, Ping Yu; Elzinga, Lawrence; Anger, Michael S.; Lee, Jean; Robert, Nurian; Chvala, Robert; Mars, Ronald L.; Vesely, Thomas; Taber, Tim; Shemin, Douglas; Shafritz, Randy; Pulliam, Joseph.

In: American Journal of Kidney Diseases, Vol. 42, No. 2, 01.08.2003, p. 315-324.

Research output: Contribution to journalArticle

Contreras, G, Liu, PY, Elzinga, L, Anger, MS, Lee, J, Robert, N, Chvala, R, Mars, RL, Vesely, T, Taber, T, Shemin, D, Shafritz, R & Pulliam, J 2003, 'A multicenter, prospective, randomized, comparative evaluation of dual- versus triple-lumen catheters for hemodialysis and apheresis in 485 patients', American Journal of Kidney Diseases, vol. 42, no. 2, pp. 315-324. https://doi.org/10.1016/S0272-6386(03)00657-7
Contreras, Gabriel ; Liu, Ping Yu ; Elzinga, Lawrence ; Anger, Michael S. ; Lee, Jean ; Robert, Nurian ; Chvala, Robert ; Mars, Ronald L. ; Vesely, Thomas ; Taber, Tim ; Shemin, Douglas ; Shafritz, Randy ; Pulliam, Joseph. / A multicenter, prospective, randomized, comparative evaluation of dual- versus triple-lumen catheters for hemodialysis and apheresis in 485 patients. In: American Journal of Kidney Diseases. 2003 ; Vol. 42, No. 2. pp. 315-324.
@article{270e8c3c2a264e82a53c8f96559a2fc0,
title = "A multicenter, prospective, randomized, comparative evaluation of dual- versus triple-lumen catheters for hemodialysis and apheresis in 485 patients",
abstract = "Background: The purpose of this study is to compare a new temporary triple-lumen catheter (TLC) for dialysis that has a third lumen devoted to fluid and medication administration or blood sampling with a marketed dual-lumen catheter (DLC). Methods: Four hundred eighty-five patients referred for acute hemodialysis or apheresis were randomly assigned to either a TLC or DLC in a multicenter, prospective, randomized trial. Results: Analysis of blood flow rates was completed on 464 patients (228 patients, DLC; 236 patients, TLC) with a total of 1,681 hemodialysis (808 treatments, DLC; 873 treatments, TLC) and 82 apheresis treatments (37 treatments, DLC; 45 treatments, TLC). During hemodialysis, a median achieved flow rate (AFR) of 267 mL/min was realized for both groups (P = 0.58). During apheresis, a median AFR of 72.5 mL/min (range, 50 to 150 mL/min) was achieved in the DLC group, and 87 mL/min (range, 60 to 150 mL/min), in the TLC group (P = 0.14). Three hundred ninety-three patients (193 patients, DLC; 200 patients, TLC) had blood and catheter tip cultures performed on removal, and catheter-related blood-stream infection (CRBSI) status was determined. Thirty-one patients (7.9{\%}) had a CRBSI: 16 patients (8.3{\%}), DLC; and 15 patients (7.5{\%}), TLC (P= 0.77). Incidence densities of CRBSI were 12.4/1,000 DLC-days and 10.2/1,000 TLC-days (P = 0.59). The CRBSI incidence of 18.2/1,000 catheter-days for femoral sites was significantly greater than the 7/1,000 catheter-days for jugular sites (P = 0.02) and 6.6/1,000 catheter-days for combined jugular and subclavian sites (P = 0.01). In multivariate analysis, antibiotic use was the only factor related to CRBSI (odds ratio, 0.30; 95{\%} confidence interval, 0.12 to 0.76). There were no statistically significant differences in rates of other complications between the 2 catheters. Conclusion: Results show that the new TLC is similar to the marketed DLC.",
keywords = "Apheresis, Hemodialysis (HD), Randomized clinical trial, Temporary triple-lumen catheter (TLC)",
author = "Gabriel Contreras and Liu, {Ping Yu} and Lawrence Elzinga and Anger, {Michael S.} and Jean Lee and Nurian Robert and Robert Chvala and Mars, {Ronald L.} and Thomas Vesely and Tim Taber and Douglas Shemin and Randy Shafritz and Joseph Pulliam",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S0272-6386(03)00657-7",
language = "English (US)",
volume = "42",
pages = "315--324",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - A multicenter, prospective, randomized, comparative evaluation of dual- versus triple-lumen catheters for hemodialysis and apheresis in 485 patients

AU - Contreras, Gabriel

AU - Liu, Ping Yu

AU - Elzinga, Lawrence

AU - Anger, Michael S.

AU - Lee, Jean

AU - Robert, Nurian

AU - Chvala, Robert

AU - Mars, Ronald L.

AU - Vesely, Thomas

AU - Taber, Tim

AU - Shemin, Douglas

AU - Shafritz, Randy

AU - Pulliam, Joseph

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background: The purpose of this study is to compare a new temporary triple-lumen catheter (TLC) for dialysis that has a third lumen devoted to fluid and medication administration or blood sampling with a marketed dual-lumen catheter (DLC). Methods: Four hundred eighty-five patients referred for acute hemodialysis or apheresis were randomly assigned to either a TLC or DLC in a multicenter, prospective, randomized trial. Results: Analysis of blood flow rates was completed on 464 patients (228 patients, DLC; 236 patients, TLC) with a total of 1,681 hemodialysis (808 treatments, DLC; 873 treatments, TLC) and 82 apheresis treatments (37 treatments, DLC; 45 treatments, TLC). During hemodialysis, a median achieved flow rate (AFR) of 267 mL/min was realized for both groups (P = 0.58). During apheresis, a median AFR of 72.5 mL/min (range, 50 to 150 mL/min) was achieved in the DLC group, and 87 mL/min (range, 60 to 150 mL/min), in the TLC group (P = 0.14). Three hundred ninety-three patients (193 patients, DLC; 200 patients, TLC) had blood and catheter tip cultures performed on removal, and catheter-related blood-stream infection (CRBSI) status was determined. Thirty-one patients (7.9%) had a CRBSI: 16 patients (8.3%), DLC; and 15 patients (7.5%), TLC (P= 0.77). Incidence densities of CRBSI were 12.4/1,000 DLC-days and 10.2/1,000 TLC-days (P = 0.59). The CRBSI incidence of 18.2/1,000 catheter-days for femoral sites was significantly greater than the 7/1,000 catheter-days for jugular sites (P = 0.02) and 6.6/1,000 catheter-days for combined jugular and subclavian sites (P = 0.01). In multivariate analysis, antibiotic use was the only factor related to CRBSI (odds ratio, 0.30; 95% confidence interval, 0.12 to 0.76). There were no statistically significant differences in rates of other complications between the 2 catheters. Conclusion: Results show that the new TLC is similar to the marketed DLC.

AB - Background: The purpose of this study is to compare a new temporary triple-lumen catheter (TLC) for dialysis that has a third lumen devoted to fluid and medication administration or blood sampling with a marketed dual-lumen catheter (DLC). Methods: Four hundred eighty-five patients referred for acute hemodialysis or apheresis were randomly assigned to either a TLC or DLC in a multicenter, prospective, randomized trial. Results: Analysis of blood flow rates was completed on 464 patients (228 patients, DLC; 236 patients, TLC) with a total of 1,681 hemodialysis (808 treatments, DLC; 873 treatments, TLC) and 82 apheresis treatments (37 treatments, DLC; 45 treatments, TLC). During hemodialysis, a median achieved flow rate (AFR) of 267 mL/min was realized for both groups (P = 0.58). During apheresis, a median AFR of 72.5 mL/min (range, 50 to 150 mL/min) was achieved in the DLC group, and 87 mL/min (range, 60 to 150 mL/min), in the TLC group (P = 0.14). Three hundred ninety-three patients (193 patients, DLC; 200 patients, TLC) had blood and catheter tip cultures performed on removal, and catheter-related blood-stream infection (CRBSI) status was determined. Thirty-one patients (7.9%) had a CRBSI: 16 patients (8.3%), DLC; and 15 patients (7.5%), TLC (P= 0.77). Incidence densities of CRBSI were 12.4/1,000 DLC-days and 10.2/1,000 TLC-days (P = 0.59). The CRBSI incidence of 18.2/1,000 catheter-days for femoral sites was significantly greater than the 7/1,000 catheter-days for jugular sites (P = 0.02) and 6.6/1,000 catheter-days for combined jugular and subclavian sites (P = 0.01). In multivariate analysis, antibiotic use was the only factor related to CRBSI (odds ratio, 0.30; 95% confidence interval, 0.12 to 0.76). There were no statistically significant differences in rates of other complications between the 2 catheters. Conclusion: Results show that the new TLC is similar to the marketed DLC.

KW - Apheresis

KW - Hemodialysis (HD)

KW - Randomized clinical trial

KW - Temporary triple-lumen catheter (TLC)

UR - http://www.scopus.com/inward/record.url?scp=10744222681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744222681&partnerID=8YFLogxK

U2 - 10.1016/S0272-6386(03)00657-7

DO - 10.1016/S0272-6386(03)00657-7

M3 - Article

C2 - 12900814

AN - SCOPUS:10744222681

VL - 42

SP - 315

EP - 324

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -